Abstract
Background: The therapeutic approaches for the management of topical infections have always been a difficult approach due to lack of efficacy of conventional topical formulations, high frequency of topical applications and non-patient compliance. The major challenge in the management of topical infections lies in antibiotic resistance which leads to severe complications and hospitalizations resulting in economic burden and high mortality rates.
Methods: Topical delivery employing lipid-based carriers has been a promising strategy to overcome the challenges of poor skin permeation and retention along with large doses which need to be administered systemically. The use of lipid-based delivery systems is a promising strategy for the effective topical delivery of antibiotics and overcoming drug-resistant strains in the skin. The major systems include transfersomes, niosomes, ethosomes, solid lipid nanoparticles, nanostructured lipid carriers, microemulsion and nanoemulsion as the most promising drug delivery approaches to treat infectious disorders. The main advantages of these systems include lipid bilayer structure which mimics the cell membrane and can fuse with infectious microbes. The numerous advantages associated with nanocarriers like enhanced efficacy, improvement in bioavailability, controlled drug release and ability to target the desired infectious pathogen have made these carriers successful.
Conclusion: Despite the number of strides taken in the field of topical drug delivery in infectious diseases, it still requires extensive research efforts to have a better perspective of the factors that influence drug permeation along with the mechanism of action with regard to skin penetration and deposition. The final objective of the therapy is to provide a safe and effective therapeutic approach for the management of infectious diseases affecting topical sites leading to enhanced therapeutic efficacy and patient-compliance.
Keywords: Skin infections, Vesicular, Microemulsion, Stratum corneum, skin barrier, antibiotic resistance.
[1]
Thakur K, Sharma G, Singh B, Chhibber S, Katare OP. Current State of Nanomedicines in the Treatment of Topical Infectious Disorders. Recent Pat Antiinfect Drug Discov 2018.
[2]
Akhtar N, Verma A, Pathak K. Topical delivery of drugs for the effective treatment of fungal infections of skin. Curr Pharm Des 2015; 21(20): 2892-913.
[3]
Lam PL, Lee KKH, Wong RSM, et al. Recent advances on topical antimicrobials for skin and soft tissue infections and their safety concerns. Crit Rev Microbiol 2018; 44(1): 40-78.
[4]
Roberts MS, Mohammed Y, Pastore MN, et al. Topical and cutaneous delivery using nanosystems. J Control Release 2017; 247: 86-105.
[5]
Sharma G, Devi N, Thakur K, Jain A, Katare OP. Lanolin-based organogel of salicylic acid: evidences of better dermatokinetic profile in imiquimod-induced keratolytic therapy in BALB/c mice model. Drug Deliv Transl Res 2018; 8(2): 398-413.
[6]
Sharma G, Thakur K, Raza K, Singh B, Katare OP. Nanostructured lipid carriers: A new paradigm in topical delivery for dermal and transdermal applications. Crit Rev Ther Drug Carrier Syst 2017; 34(4): 355-86.
[7]
Lalani R, Misra A, Amrutiya J, Patel H, Bhatt P, Patel V. Challenges in dermal delivery of therapeutic antimicrobial protein and peptides. Curr Drug Metab 2017; 18(5): 426-36.
[8]
Hsu CY, Yang SC, Sung CT, Weng YH, Fang JY. Anti-MRSA malleable liposomes carrying chloramphenicol for ameliorating hair follicle targeting. Int J Nanomedicine 2017; 12: 8227-38.
[9]
Prabhu P, Patravale V, Joshi M. Nanocarriers for effective topical delivery of anti-infectives. Curr Nanosci 2012; 8: 491-503.
[10]
Bseiso EA, Nasr M, Sammour O, Abd El Gawad NA. Recent advances in topical formulation carriers of antifungal agents. Indian J Dermatol Venereol Leprol 2015; 81(5): 457-63.
[11]
Desai P, Patlolla RR, Singh M. Interaction of nanoparticles and cell-penetrating peptides with skin for transdermal drug delivery. Mol Membr Biol 2010; 27(7): 247-59.
[12]
Cox NH, Colver GB, Paterson WD. Management and morbidity of cellulitis of the leg. J R Soc Med 1998; 91(12): 634-7.
[14]
Brook I, Frazier EH. Clinical and microbiological features of necrotizing fasciitis. J Clin Microbiol 1995; 33(9): 2382-7.
[15]
Bisno AL, Stevens DL. Streptococcal infections of skin and soft tissues. N Engl J Med 1996; 334(4): 240-5.
[16]
Hay RJ. Overview of studies of fluconazole in oropharyngeal candidiasis. Rev Infect Dis 1990; 12(Suppl. 3): S334-7.
[17]
Drake LA, Dinehart SM, Farmer ER, et al. Guidelines of care for superficial mycotic infections of the skin: Pityriasis (tinea) versicolor. J Am Acad Dermatol 1996; 34(2 Pt 1): 287-9.
[19]
Cevc G, Vierl U. Nanotechnology and the transdermal route: A state of the art review and critical appraisal. J Control Release 2010; 141(3): 277-99.
[20]
Gray GM, White RJ, Williams RH, Yardley HJ. Lipid composition of the superficial stratum corneum cells of pig epidermis. Br J Dermatol 1982; 106(1): 59-63.
[21]
Wertz PW, Swartzendruber DC, Kitko DJ, Madison KC, Downing DT. The role of the corneocyte lipid envelopes in cohesion of the stratum corneum. J Invest Dermatol 1989; 93(1): 169-72.
[22]
Burgeson RE, Christiano AM. The dermal-epidermal junction. Curr Opin Cell Biol 1997; 9(5): 651-8.
[23]
Kanikkannan N, Singh J, Ramarao P. Transdermal iontophoretic delivery of timolol maleate in albino rabbits. Int J Pharm 2000; 197(1-2): 69-76.
[24]
Sharma G, Thakur K, Setia A, et al. Fabrication of acyclovir-loaded flexible membrane vesicles (FMVs): evidence of preclinical efficacy of antiviral activity in murine model of cutaneous HSV-1 infection. Drug Deliv Transl Res 2017; 7(5): 683-94.
[25]
Katare OP, Raza K, Singh B, Dogra S. Novel drug delivery systems in topical treatment of psoriasis: Rigors and vigors. Indian J Dermatol Venereol Leprol 2010; 76(6): 612-21.
[26]
Sharma G, Goyal H, Thakur K, Raza K, Katare OP. Novel elastic membrane vesicles (EMVs) and ethosomes-mediated effective topical delivery of aceclofenac: A new therapeutic approach for pain and inflammation. Drug Deliv 2016; 23(8): 3135-45.
[27]
Sharma G, Saini MK, Thakur K, et al. Aceclofenac cocrystal nanoliposomes for rheumatoid arthritis with better dermatokinetic attributes: A preclinical study. Nanomedicine (Lond) 2017; 12(6): 615-38.
[28]
Jain A, Garg NK, Jain A, et al. A synergistic approach of adapalene-loaded nanostructured lipid carriers, and vitamin C co-administration for treating acne. Drug Dev Ind Pharm 2016; 42(6): 897-905.
[29]
Bragagni M, Mennini N, Maestrelli F, Cirri M, Mura P. Comparative study of liposomes, transfersomes and ethosomes as carriers for improving topical delivery of celecoxib. Drug Deliv 2012; 19(7): 354-61.
[30]
Touitou E, Ainbinde D. 7. Ethosomes - an innovative carrier for enhanced delivery into and across the skin: Original research article: Ethosomes - novel vesicular carriers for enhanced delivery: characterization skin penetration properties, 2000. J Control Release 2014; 190: 44-6.
[31]
Rukavina Z, Vanić Ž. Current trends in development of liposomes for targeting bacterial biofilms. Pharmaceutics 2016; 8(2): E18.
[32]
Nunes PS, Rabelo AS, Souza JC, et al. Gelatin-based membrane containing usnic acid-loaded liposome improves dermal burn healing in a porcine model. Int J Pharm 2016; 513(1-2): 473-82.
[33]
Jøraholmen MW, Škalko-Basnet N, Acharya G, Basnet P. Resveratrol-loaded liposomes for topical treatment of the vaginal inflammation and infections. Eur J Pharm Sci 2015; 79: 112-21.
[34]
Wadhwa S, Singh B, Sharma G, Raza K, Katare OP. Liposomal fusidic acid as a potential delivery system: A new paradigm in the treatment of chronic plaque psoriasis. Drug Deliv 2016; 23(4): 1204-13.
[35]
Varikuti S, Oghumu S, Saljoughian N, et al. Topical treatment with nanoliposomal Amphotericin B reduces early lesion growth but fails to induce cure in an experimental model of cutaneous leishmaniasis caused by Leishmania mexicana. Acta Trop 2017; 173: 102-8.
[36]
Tanrıverdi ST, Özer Ö. Novel topical formulations of Terbinafine-HCl for treatment of onychomycosis. Eur J Pharm Sci 2013; 48(4-5): 628-36.
[37]
Benson HA. Transfersomes for transdermal drug delivery. Expert Opin Drug Deliv 2006; 3(6): 727-37.
[38]
Cevc G, Blume G. New, highly efficient formulation of diclofenac for the topical, transdermal administration in ultradeformable drug carriers, Transfersomes. Biochim Biophys Acta 2001; 1514(2): 191-205.
[39]
Hussain A, Singh S, Webster TJ, Ahmad FJ. New perspectives in the topical delivery of optimized amphotericin B loaded nanoemulsions using excipients with innate anti-fungal activities: A mechanistic and histopathological investigation. Nanomedicine (Lond) 2017; 13(3): 1117-26.
[40]
Hussain A, Singh S, Sharma D, Webster TJ, Shafaat K, Faruk A. Elastic liposomes as novel carriers: recent advances in drug delivery. Int J Nanomedicine 2017; 12: 5087-108.
[41]
Li C, Zhang X, Huang X, Wang X, Liao G, Chen Z. Preparation and characterization of flexible nanoliposomes loaded with daptomycin, a novel antibiotic, for topical skin therapy. Int J Nanomedicine 2013; 8: 1285-92.
[42]
Pandit J, Garg M, Jain NK. Miconazole nitrate bearing ultraflexible liposomes for the treatment of fungal infection. J Liposome Res 2014; 24(2): 163-9.
[43]
Qushawy M, Nasr A, Abd-Alhaseeb M, Swidan S. Design, optimization and characterization of a transfersomal gel using miconazole nitrate for the treatment of candida skin infections. Pharmaceutics 2018; 10(1): E26.
[44]
Chhibber S, Shukla A, Kaur S. Transfersomal phage cocktail is an effective treatment against methicillin-resistant Staphylococcus aureus-mediated skin and soft tissue infections. Antimicrob Agents Chemother 2017; 61(10): e02146-16.
[45]
Bavarsad N, Fazly Bazzaz BS, Khamesipour A, Jaafari MR. Colloidal, in vitro and in vivo anti-leishmanial properties of transfersomes containing paromomycin sulfate in susceptible BALB/c mice. Acta Trop 2012; 124(1): 33-41.
[46]
Park H, Lee J, Jeong S, et al. Lipase-sensitive transfersomes based on photosensitizer/polymerizable lipid conjugate for selective antimicrobial photodynamic therapy of acne. Adv Healthc Mater 2016; 5(24): 3139-47.
[47]
Hamishehkar H, Rahimpour Y, Kouhsoltani M. Niosomes as a propitious carrier for topical drug delivery. Expert Opin Drug Deliv 2013; 10(2): 261-72.
[48]
Azeem A, Anwer MK, Talegaonkar S. Niosomes in sustained and targeted drug delivery: Some recent advances. J Drug Target 2009; 17(9): 671-89.
[49]
Sohrabi S, Haeri A, Mahboubi A, Mortazavi A, Dadashzadeh S. Chitosan gel-embedded moxifloxacin niosomes: An efficient antimicrobial hybrid system for burn infection. Int J Biol Macromol 2016; 85: 625-33.
[50]
Khalil RM, Abdelbary GA, Basha M, Awad GE, El-Hashemy HA. Design and evaluation of proniosomes as a carrier for ocular delivery of lomefloxacin HCl. J Liposome Res 2017; 27(2): 118-29.
[51]
Jain S, Jain S, Khare P, Gulbake A, Bansal D, Jain SK. Design and development of solid lipid nanoparticles for topical delivery of an anti-fungal agent. Drug Deliv 2010; 17(6): 443-51.
[52]
Kaur L, Jain SK, Manhas RK, Sharma D. Nanoethosomal formulation for skin targeting of amphotericin B: An in vitro and in vivo assessment. J Liposome Res 2015; 25(4): 294-307.
[54]
Marto J, Vitor C, Guerreiro A, et al. Ethosomes for enhanced skin delivery of griseofulvin. Colloids Surf B Biointerfaces 2016; 146: 616-23.
[55]
Shetty S, Jose J, Kumar L, Charyulu RN. Novel ethosomal gel of clove oil for the treatment of cutaneous candidiasis. J Cosmet Dermatol 2018; •••
[http://dx.doi.org/10.1111/jocd.12765]
[http://dx.doi.org/10.1111/jocd.12765]
[56]
Guo F, Wang J, Ma M, Tan F, Li N. Skin targeted lipid vesicles as novel nano-carrier of ketoconazole: Characterization, in vitro and in vivo evaluation. J Mater Sci Mater Med 2015; 26(4): 175.
[57]
Abdellatif MM, Khalil IA, Khalil MAF. Sertaconazole nitrate loaded nanovesicular systems for targeting skin fungal infection: In-vitro, ex-vivo and in-vivo evaluation. Int J Pharm 2017; 527(1-2): 1-11.
[58]
Godin B, Touitou E. Erythromycin ethosomal systems: Physicochemical characterization and enhanced antibacterial activity. Curr Drug Deliv 2005; 2(3): 269-75.
[59]
Gupta M, Vyas SP. Development, characterization and in vivo assessment of effective lipidic nanoparticles for dermal delivery of fluconazole against cutaneous candidiasis. Chem Phys Lipids 2012; 165(4): 454-61.
[60]
Raza K, Singh B, Singal P, Wadhwa S, Katare OP. Systematically optimized biocompatible isotretinoin-loaded solid lipid nanoparticles (SLNs) for topical treatment of acne. Colloids Surf B Biointerfaces 2013; 105: 67-74.
[61]
Trombino S, Mellace S, Cassano R. Solid lipid nanoparticles for antifungal drugs delivery for topical applications. Ther Deliv 2016; 7(9): 639-47.
[62]
Naseri N, Valizadeh H, Zakeri-Milani P. Solid lipid nanoparticles and nanostructured lipid carriers: structure, preparation and application. Adv Pharm Bull 2015; 5(3): 305-13.
[63]
Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm 2000; 50(1): 161-77.
[64]
Saupe A, Gordon KC, Rades T. Structural investigations on nanoemulsions, solid lipid nanoparticles and nanostructured lipid carriers by cryo-field emission scanning electron microscopy and Raman spectroscopy. Int J Pharm 2006; 314(1): 56-62.
[65]
Prow TW, Grice JE, Lin LL, et al. Nanoparticles and microparticles for skin drug delivery. Adv Drug Deliv Rev 2011; 63(6): 470-91.
[66]
Papakostas D, Rancan F, Sterry W, Blume-Peytavi U, Vogt A. Nanoparticles in dermatology. Arch Dermatol Res 2011; 303(8): 533-50.
[67]
El-Housiny S, Shams Eldeen MA, El-Attar YA, et al. Fluconazole-loaded solid lipid nanoparticles topical gel for treatment of pityriasis versicolor: Formulation and clinical study. Drug Deliv 2018; 25(1): 78-90.
[68]
Chetoni P, Burgalassi S, Monti D, et al. Solid lipid nanoparticles as promising tool for intraocular tobramycin delivery: Pharmacokinetic studies on rabbits. Eur J Pharm Biopharm 2016; 109: 214-23.
[69]
Vaghasiya H, Kumar A, Sawant K. Development of solid lipid nanoparticles based controlled release system for topical delivery of terbinafine hydrochloride. Eur J Pharm Sci 2013; 49(2): 311-22.
[71]
Fumakia M, Ho EA. Nanoparticles encapsulated with LL37 and serpin A1 promotes wound healing and synergistically enhances antibacterial activity. Mol Pharm 2016; 13(7): 2318-31.
[72]
Kalhapure RS, Sikwal DR, Rambharose S, et al. Enhancing targeted antibiotic therapy via pH responsive solid lipid nanoparticles from an acid cleavable lipid. Nanomedicine (Lond) 2017; 13(6): 2067-77.
[73]
Fazly Bazzaz BS, Khameneh B, Zarei H, Golmohammadzadeh S. Antibacterial efficacy of rifampin loaded solid lipid nanoparticles against Staphylococcus epidermidis biofilm. Microb Pathog 2016; 93: 137-44.
[74]
Zhu L, Cao X, Xu Q, Su J, Li X, Zhou W. Evaluation of the antibacterial activity of tilmicosin-SLN against Streptococcus agalactiae: in vitro and in vivo studies. Int J Nanomedicine 2018; 13: 4747-55.
[75]
Müller RH, Petersen RD, Hommoss A, Pardeike J. Nanostructured lipid carriers (NLC) in cosmetic dermal products. Adv Drug Deliv Rev 2007; 59(6): 522-30.
[76]
Müller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev 2002; 54(Suppl. 1): S131-55.
[77]
Yong CS, Li DX, Prabagar B, et al. The effect of beta-cyclodextrin complexation on the bioavailability and hepatotoxicity of clotrimazole. Pharmazie 2007; 62(10): 756-9.
[78]
Souto EB, Wissing SA, Barbosa CM, Müller RH. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int J Pharm 2004; 278(1): 71-7.
[79]
Das S, Ng WK, Tan RB. Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): Development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs? Eur J Pharm Sci 2012; 47(1): 139-51.
[80]
Souto EB, Müller RH. SLN and NLC for topical delivery of ketoconazole. J Microencapsul 2005; 22(5): 501-10.
[81]
Ravani L, Esposito E, Bories C, et al. Clotrimazole-loaded nanostructured lipid carrier hydrogels: Thermal analysis and in vitro studies. Int J Pharm 2013; 454(2): 695-702.
[82]
Singh S, Singh M, Tripathi CB, Arya M, Saraf SA. Development and evaluation of ultra-small nanostructured lipid carriers: novel topical delivery system for athlete’s foot. Drug Deliv Transl Res 2016; 6(1): 38-47.
[83]
Stecová J, Mehnert W, Blaschke T, et al. Cyproterone acetate loading to lipid nanoparticles for topical acne treatment: Particle characterisation and skin uptake. Pharm Res 2007; 24(5): 991-1000.
[84]
Raza K, Singh B, Lohan S, et al. Nano-lipoidal carriers of tretinoin with enhanced percutaneous absorption, photostability, biocompatibility and anti-psoriatic activity. Int J Pharm 2013; 456(1): 65-72.
[85]
Bose S, Michniak-Kohn B. Preparation and characterization of lipid based nanosystems for topical delivery of quercetin. Eur J Pharm Sci 2013; 48(3): 442-52.
[86]
Charoenputtakhun P, Opanasopit P, Rojanarata T, Ngawhirunpat T. All-trans retinoic acid-loaded lipid nanoparticles as a transdermal drug delivery carrier. Pharm Dev Technol 2014; 19(2): 164-72.
[87]
Lin YK, Huang ZR, Zhuo RZ, Fang JY. Combination of calcipotriol and methotrexate in nanostructured lipid carriers for topical delivery. Int J Nanomedicine 2010; 5: 117-28.
[88]
Lewies A, Wentzel JF, Jordaan A, Bezuidenhout C, Du Plessis LH. Interactions of the antimicrobial peptide nisin Z with conventional antibiotics and the use of nanostructured lipid carriers to enhance antimicrobial activity. Int J Pharm 2017; 526(1-2): 244-53.
[89]
Alalaiwe A, Wang PW, Lu PL, Chen YP, Fang JY, Yang SC. Synergistic Anti-MRSA activity of cationic nanostructured lipid carriers in combination with oxacillin for cutaneous application. Front Microbiol 2018; 9: 1493.
[90]
Song SH, Lee KM, Kang JB, Lee SG, Kang MJ, Choi YW. Improved skin delivery of voriconazole with a nanostructured lipid carrier-based hydrogel formulation. Chem Pharm Bull (Tokyo) 2014; 62(8): 793-8.
[91]
Moreno-Sastre M, Pastor M, Esquisabel A, et al. Pulmonary delivery of tobramycin-loaded nanostructured lipid carriers for Pseudomonas aeruginosa infections associated with cystic fibrosis. Int J Pharm 2016; 498(1-2): 263-73.
[92]
Fu T, Yi J, Lv S, Zhang B. Ocular amphotericin B delivery by chitosan-modified nanostructured lipid carriers for fungal keratitis-targeted therapy. J Liposome Res 2017; 27(3): 228-33.
[93]
Dave V, Kushwaha K, Yadav RB, Agrawal U. Hybrid nanoparticles for the topical delivery of norfloxacin for the effective treatment of bacterial infection produced after burn. J Microencapsul 2017; 34(4): 351-65.
[94]
Forier K, Raemdonck K, De Smedt SC, Demeester J, Coenye T, Braeckmans K. Lipid and polymer nanoparticles for drug delivery to bacterial biofilms. J Control Release 2014; 190: 607-23.
[95]
Thakur K, Sharma G, Singh B, Chhibber S, Patil AB, Katare OP. Chitosan-tailored lipidic nanoconstructs of Fusidic acid as promising vehicle for wound infections: An explorative study. Int J Biol Macromol 2018; 115: 1012-25.
[96]
Seedat N, Kalhapure RS, Mocktar C, et al. Co-encapsulation of multi-lipids and polymers enhances the performance of vancomycin in lipid-polymer hybrid nanoparticles: in vitro and in silico studies. Mater Sci Eng C 2016; 61: 616-30.
[97]
Sonawane SJ, Kalhapure RS, Rambharose S, et al. Ultra-small lipid-dendrimer hybrid nanoparticles as a promising strategy for antibiotic delivery: in vitro and in silico studies. Int J Pharm 2016; 504(1-2): 1-10.
[98]
Cao S, Jiang Y, Zhang H, Kondza N, Woodrow KA. Core-shell nanoparticles for targeted and combination antiretroviral activity in gut-homing T cells. Nanomedicine (Lond) 2018; 14(7): 2143-53.
[99]
Boonme P, Kaewbanjong J, Amnuaikit T, Andreani T, Silva AM, Souto EB. Microemulsion and microemulsion-based gels for topical antifungal therapy with phytochemicals. Curr Pharm Des 2016; 22(27): 4257-63.
[100]
Negi P, Singh B, Sharma G, Beg S, Raza K, Katare OP. Phospholipid microemulsion-based hydrogel for enhanced topical delivery of lidocaine and prilocaine: QbD-based development and evaluation. Drug Deliv 2016; 23(3): 951-67.
[101]
Sharma G, Dhankar G, Thakur K, Raza K, Katare OP. Benzyl benzoate-loaded microemulsion for topical applications: Enhanced dermatokinetic profile and better delivery promises. AAPS PharmSciTech 2016; 17(5): 1221-31.
[102]
Hussain A, Samad A, Singh SK, et al. Nanoemulsion gel-based topical delivery of an antifungal drug: In vitro activity and in vivo evaluation. Drug Deliv 2016; 23(2): 642-7.
[103]
Thakur K, Sharma G, Singh B, et al. Cationic-bilayered nanoemulsion of fusidic acid: An investigation on eradication of methicillin-resistant Staphylococcus aureus 33591 infection in burn wound. Nanomedicine (Lond) 2018; 13(8): 825-47.
[104]
Choudhury H, Gorain B, Pandey M, et al. Recent update on nanoemulgel as topical drug delivery system. J Pharm Sci 2017; 106(7): 1736-51.
[105]
Calderilla-Fajardo SB, Cázares-Delgadillo J, Villalobos-García R, Quintanar-Guerrero D, Ganem-Quintanar A, Robles R. Influence of sucrose esters on the in vivo percutaneous penetration of octyl methoxycinnamate formulated in nanocapsules, nanoemulsion, and emulsion. Drug Dev Ind Pharm 2006; 32(1): 107-13.
[106]
Wan T, Xu T, Pan J, et al. Microemulsion based gel for topical dermal delivery of pseudolaric acid B: In vitro and in vivo evaluation. Int J Pharm 2015; 493(1-2): 111-20.
[107]
Kumar N. Shishu. D-optimal experimental approach for designing topical microemulsion of itraconazole: Characterization and evaluation of antifungal efficacy against a standardized Tinea pedis infection model in Wistar rats. Eur J Pharm Sci 2015; 67: 97-112.
[108]
Chhibber T, Wadhwa S, Chadha P, Sharma G, Katare OP. Phospholipid structured microemulsion as effective carrier system with potential in methicillin sensitive Staphylococcus aureus (MSSA) involved burn wound infection. J Drug Target 2015; 23(10): 943-52.
[109]
Kaur A, Sharma G, Gupta V, Ratho RK, Katare OP. Enhanced acyclovir delivery using w/o type microemulsion: Preclinical assessment of antiviral activity using murine model of zosteriform cutaneous HSV-1 infection. Artif Cells Nanomed Biotechnol 2018; 46(2): 346-54.
[110]
Rastogi V, Yadav P, Verma A, Pandit JK. Ex vivo and in vivo evaluation of microemulsion based transdermal delivery of E. coli specific T4 bacteriophage: A rationale approach to treat bacterial infection. Eur J Pharm Sci 2017; 107: 168-82.
[111]
Bharti SK, Kesavan K. Phase-transition W/O microemulsions for ocular delivery: Evaluation of antibacterial activity in the treatment of bacterial keratitis. Ocul Immunol Inflamm 2017; 25(4): 463-74.
[112]
Sosa L, Clares B, Alvarado HL, Bozal N, Domenech O, Calpena AC. Amphotericin B releasing topical nanoemulsion for the treatment of candidiasis and aspergillosis. Nanomedicine (Lond) 2017; 13(7): 2303-12.
[113]
Cao Z, Spilker T, Fan Y, et al. Nanoemulsion is an effective antimicrobial for methicillin-resistant Staphylococcus aureus in infected wounds. Nanomedicine (Lond) 2017; 12(10): 1177-85.
[114]
Fan Y, Ciotti S, Cao Z, Eisma R, Baker J Jr, Wang SH. Screening of nanoemulsion formulations and identification of NB-201 as an effective topical antimicrobial for Staphylococcus aureus in a mouse model of infected wounds. Mil Med 2016; 181(5)(Suppl.): 259-64.
[115]
Dolgachev VA, Ciotti SM, Eisma R, et al. Nanoemulsion therapy for burn wounds is effective as a topical antimicrobial against gram-negative and gram-positive bacteria. J Burn Care Res 2016; 37(2): e104-14.
[116]
Mahtab A, Anwar M, Mallick N, Naz Z, Jain GK, Ahmad FJ. Transungual delivery of ketoconazole nanoemulgel for the effective management of onychomycosis. AAPS PharmSciTech 2016; 17(6): 1477-90.
[117]
Kelmann RG, Colombo M, De Araújo Lopes SC, et al. Pentyl gallate nanoemulsions as potential topical treatment of herpes labialis. J Pharm Sci 2016; 105(7): 2194-203.
[118]
Song Z, Sun H, Yang Y, et al. Enhanced efficacy and anti-biofilm activity of novel nanoemulsions against skin burn wound multi-drug resistant MRSA infections. Nanomedicine (Lond) 2016; 12(6): 1543-55.
[119]
Connell S, Li J, Durkes A, Zaroura M, Shi R. Nondermal irritating hyperosmotic nanoemulsions reduce treatment times in a contamination model of wound healing. Wound Repair Regen 2016; 24(4): 669-78.
[120]
Nair A, Jacob IIS, Al-DhubiabI B, Attimarad IM, Harsha IS. Basic considerations in the dermatokinetics of topical formulations. Braz J Pharm Sci 2013; 49(3): 423-34.
[121]
Thotakura N, Kumar P, Wadhwa S, Raza K, Katare P. Dermatokinetics as an important tool to assess the bioavailability of drugs by topical nanocarriers. Curr Drug Metab 2017; 18(5): 404-11.
[122]
Industry Gf. Topical dermatologic corticosteroids: in vivo bioequivalence.administration USDoHaHSRFad 1995; 1-36.
[123]
Shah VP. opical dermatological drug product NDAs and ANDAsin vivo bioavailability, bioequivalence, in vitro release and associated studies.Services RUDoHaH 1998; 1-19.
[124]
Yedgar S, Ojcius D. Use of lipid conjugates in the treatment of infection. Yissum Research Development Co of Hebrew University 2009.
[125]
Touitou E. Stable compositions for nail onychomycosis treatment. Galderma Pharma SaYissum Research Development Company Of The Hebrew University Of Jerusalem 2009.
[127]
Shenoy D, Lee R, Wright C. Nanostructured compositions having antibacterial, anti-fungal, anti-yeast, and/or anti-viral properties. Novavax, Inc 2007.
[128]
Seabra CL. Nanostructurated lipid carriers, methods and uses thereof. Ineb - Instituto Nacional De Engenharia BiomédicaUniversidade Do Porto 2018.
[129]
Reghal A, Potel G, Caillon J, Jacqueline C, Asehoune K, Gonnet MTP. Lipid nanoparticles comprising an antibiotic and their use in therapy. Atlangram 2015.
[130]
Baker JR, Flack MR, Ciotti SM, Sutcliffe JA. Methods of treating fungal, yeast and mold infections. Nanobio Corp 2008.
[131]
Venugopalarao G, Lakshmipathy R, Sarada NC. Preparation and characterization of cefditoren pivoxil-loaded liposomes for controlled in vitroand in vivo drug release. Int J Nanomedicine 2015; 10(Suppl. 1): 149-57.
[132]
El-Ridy MS, Abdelbary A, Essam T, El-Salam RM, Kassem AA. Niosomes as a potential drug delivery system for increasing the efficacy and safety of nystatin. Drug Dev Ind Pharm 2011; 37(12): 1491-508.
[133]
Rajinikanth PS, Chellian J. Development and evaluation of nanostructured lipid carrier-based hydrogel for topical delivery of 5-fluorouracil. Int J Nanomedicine 2016; 11: 5067-77.
[134]
Pastor M, Moreno-Sastre M, Esquisabel A, et al. Sodium colistimethate loaded lipid nanocarriers for the treatment of Pseudomonas aeruginosa infections associated with cystic fibrosis. Int J Pharm 2014; 477(1-2): 485-94.
[135]
Fernández-Campos F, Clares Naveros B, López Serrano O, Alonso Merino C, Calpena Campmany AC. Evaluation of novel nystatin nanoemulsion for skin candidosis infections. Mycoses 2013; 56(1): 70-81.
[136]
Quatrin PM, Verdi CM, de Souza ME, et al. Antimicrobial and antibiofilm activities of nanoemulsions containing Eucalyptus globulus oil against Pseudomonas aeruginosa and Candida spp. Microb Pathog 2017; 112: 230-42.
Call for Papers in Thematic Issues
30 July, 2024
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
18 September, 2024
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
29 September, 2024
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
30 June, 2024
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
Related Journals
Anti-Cancer Agents in Medicinal Chemistry
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Current Bioactive Compounds
Current Cancer Drug Targets
Combinatorial Chemistry & High Throughput Screening
Current Cancer Therapy Reviews
Current Diabetes Reviews
Current Drug Safety
Current Drug Targets
Current Drug Therapy
Related Books
Drug Addiction Mechanisms in the Brain
The NLRP3 Inflammasome: An Attentive Arbiter of Inflammatory Response
Software and Programming Tools in Pharmaceutical Research
Objective Pharmaceutics: A Comprehensive Compilation of Questions and Answers for Pharmaceutics Exam Prep
Medicinal Chemistry of Drugs Affecting Cardiovascular and Endocrine Systems
Advanced Pharmacy
Plant-derived Hepatoprotective Drugs
The Role of Chromenes in Drug Discovery and Development
New Avenues in Drug Discovery and Bioactive Natural Products
Practice and Re-Emergence of Herbal Medicine
Article Metrics
58
5
1
